17 results on '"Dichgans, Martin"'
Search Results
2. Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL
- Author
-
Dichgans, Martin, Markus, Hugh S, Salloway, Stephen, Verkkoniemi, Auli, Moline, Margaret, Wang, Qin, Posner, Holly, and Chabriat, Hugues S
- Subjects
- *
PARASYMPATHOMIMETIC agents , *CHOLINESTERASE inhibitors , *DEMENTIA , *ALZHEIMER'S disease , *MEDICAL sciences - Abstract
Summary: Background: Cholinergic deficits might contribute to vascular cognitive impairment. Trials of cholinesterase inhibitors in patients with vascular dementia are difficult because of heterogeneous disease mechanisms and overlap between vascular and Alzheimer''s disease (AD) pathology in the age-group recruited. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL) is a genetic form of subcortical ischaemic vascular dementia. It represents a homogeneous disease process, and because of CADASIL''s early onset, comorbid AD pathology is rare. We did a multicentre, 18-week, placebo-controlled, double-blind, randomised parallel-group trial to determine whether the cholinesterase inhibitor donepezil improves cognition in patients with CADASIL. Methods: 168 patients with CADASIL (mean age 54·8 years) were assigned to 10 mg donepezil per day (n=86) or placebo (n=82) by a computer-generated randomisation protocol. Inclusion criteria included a mini-mental state examination (MMSE) score of 10–27 or a trail making test (TMT) B time score at least 1·5 SD below the mean, after adjustment for age and education. The primary endpoint was change from baseline in the score on the vascular AD assessment scale cognitive subscale (V-ADAS-cog) at 18 weeks. Secondary endpoints included scores on the ADAS-cog, MMSE, TMT A time and B time, Stroop, executive interview-25 (EXIT25), CLOX, disability assessment for dementia, and sum of boxes of the clinical dementia rating scale. Analysis was done by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00103948. Findings: 161 patients were analysed. There was no significant difference between donepezil (n=84) and placebo (n=77) in the primary endpoint. The least-squares mean change from baseline score was −0·81 (SE 0·59) in the placebo group and −0·85 (SE 0·57) in the donepezil group (p=0·956). There was a significant treatment effect favouring donepezil on the following secondary outcomes: TMT B time (p=0·023), TMT A time (p=0·015), and EXIT25 (p=0·022). Ten donepezil-treated patients discontinued treatment due to adverse events compared to seven placebo-treated patients. Interpretation: Donepezil had no effect on the primary endpoint, the V-ADAS-cog score in CADASIL patients with cognitive impairment. Improvements were noted on several measures of executive function, but the clinical relevance of these findings is not clear. Our findings may have implications for future trial design in subcortical vascular cognitive impairment. Funding: Eisai Medical Research (Ridgefield Park, NJ, USA). [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
3. CADASIL presenting with a movement disorder: a clinical study of a Chilean kindred.
- Author
-
Miranda, Marcelo, Dichgans, Martin, Slachevsky, Andrea, Urbina, Francisco, Mena, Ismael, Venegas, Pablo, and Galvez, Marcelo
- Subjects
- *
DIAGNOSIS of dementia , *BIOPSY , *BRAIN , *CEREBRAL ventricles , *CELL receptors , *CEREBRAL ischemia , *DEMENTIA , *DIFFERENTIAL diagnosis , *DIAGNOSTIC imaging , *ELECTRON microscopy , *ENDOTHELIUM , *FACIAL muscles , *GENEALOGY , *GENES , *GENETIC techniques , *DIGITAL image processing , *LIMBIC system , *LONGITUDINAL method , *NEUROPSYCHOLOGICAL tests , *MICROCIRCULATION , *SKIN , *TEMPORAL lobe , *THREE-dimensional imaging , *DISEASE progression , *MEIGE syndrome , *CADASIL syndrome , *SEQUENCE analysis , *DIAGNOSIS - Abstract
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is a hereditary vascular disease that usually begins with migraine, followed by repeated strokes and progressive dementia. We describe an unusual clinical presentation of this condition in members of a Chilean family with an established NOTCH3 mutation. We report early clinical, neuropsychological, transcranial ultrasound, magnetic resonance imaging (MRI), cerebral blood flow, and skin biopsy findings on these patients. Of the patients, 2 presented with facial dystonia, 1 of whom had abnormal single photon emission computed tomography and transcranial ultrasound studies after normal brain MRI scans. Our report emphasizes that CADASIL must be considered in the study of patients with secondary dystonia. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
4. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy: Phenotypic and mutational spectrum
- Author
-
Dichgans, Martin
- Subjects
- *
CEREBROVASCULAR disease risk factors , *DEMENTIA - Abstract
Mutations in NOTCH3 are the cause of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) an inherited small vessel disease leading to subcortical strokes and dementia. Since the vascular pathology is clearly defined, CADASIL may provide important insights into the mechanisms underlying lacunar infarcts, ischemic white matter changes, and vascular dementia. Evidence from different sources suggests a central role for vascular smooth muscle cells (VSMC) in the pathophysiology of the disease. This article gives a brief overview on the phenotypic spectrum of the disease and discusses some of the relevant disease mechanisms that lead from Notch3 mutations to ischemic infarcts. [Copyright &y& Elsevier]
- Published
- 2002
- Full Text
- View/download PDF
5. Spatial Patterns of Longitudinal Gray Matter Change as Predictors of Concurrent Cognitive Decline in Amyloid Positive Healthy Subjects.
- Author
-
Caballero, Miguel Angel Araque, Kloppel, Stefan, Dichgans, Martin, and Ewers, Michael
- Subjects
- *
GRAY matter (Nerve tissue) , *AMYLOID , *ALZHEIMER'S disease risk factors , *DEMENTIA , *COGNITIVE psychology - Abstract
A substantial proportion of cognitively healthy elders (HC) show abnormally high amyloid-β (Aβ) deposition, a major pathology of Alzheimer's disease (AD). These subjects are at increased risk of Alzheimer's disease (AD) dementia, and biomarkers are needed to predict their cognitive deterioration. Here we used relevance vector regression (RVR), a pattern-recognition method, to predict concurrent cognitive decline on the basis of longitudinal gray matter (GM) changes, within two a priori, meta-analytically defined functional networks subserving episodic memory and executive function. Ninety-six HC subjects were assessed annually for three years with structural MRI and cognitive tests within the Alzheimer's Disease Neuroimaging Initiative. Presence of abnormal biomarker values of Aβ (Aβ+) were determined with cerebrospinal fluid and amyloid-PET (HC-Aβ+, n = 30; with n = 66 for normal HC-Aβ-). Using leave-one-out cross-validation, we found that in HC-Aβ+patterns of GM changes within both networks predicted decline in episodic memory (r = 0.61, p < 0.001; r = 0.40, p = 0.03), but not executive function. In HC-Aβ-, GM changes within the executive function network predicted decline in executive function (r = 0.44,p < 0.001). Previously established region-of-interest (ROI)-based predictors such as changes in hippocampal volume, within an AD-signature multi-ROI, or total GM volume were not predictive of cognitive decline in any group or cognitive domain. RVR analyses unrestricted to the a priori networks yielded compatible results with the restricted case. In conclusion, RVR-derived patterns of subtle cortical GM changes are biomarker candidates of concurrent cognitive decline in aging and subjects at risk for AD. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
6. Genetic factors in cerebral small vessel disease and their impact on stroke and dementia.
- Author
-
Haffner, Christof, Malik, Rainer, and Dichgans, Martin
- Published
- 2016
- Full Text
- View/download PDF
7. Tau-PET and in vivo Braak-staging as prognostic markers of future cognitive decline in cognitively normal to demented individuals.
- Author
-
Biel, Davina, Brendel, Matthias, Rubinski, Anna, Buerger, Katharina, Janowitz, Daniel, Dichgans, Martin, and Franzmeier, Nicolai
- Subjects
- *
PROGNOSIS , *OLDER people , *COGNITION disorders , *MILD cognitive impairment , *DEMENTIA , *EPISODIC memory , *COGNITION - Abstract
Background: To systematically examine the clinical utility of tau-PET and Braak-staging as prognostic markers of future cognitive decline in older adults with and without cognitive impairment. Methods: In this longitudinal study, we included 396 cognitively normal to dementia subjects with 18F-Florbetapir/18F-Florbetaben-amyloid-PET, 18F-Flortaucipir-tau-PET and ~ 2-year cognitive follow-up. Annual change rates in global cognition (i.e., MMSE, ADAS13) and episodic memory were calculated via linear-mixed models. We determined global amyloid-PET (Centiloid) plus global and Braak-stage-specific tau-PET SUVRs, which were stratified as positive(+)/negative(−) at pre-established cut-offs, classifying subjects as Braak0/BraakI+/BraakI–IV+/BraakI–VI+/Braakatypical+. In bootstrapped linear regression, we assessed the predictive accuracy of global tau-PET SUVRs vs. Centiloid on subsequent cognitive decline. To test for independent tau vs. amyloid effects, analyses were further controlled for the contrary PET-tracer. Using ANCOVAs, we tested whether more advanced Braak-stage predicted accelerated future cognitive decline. All models were controlled for age, sex, education, diagnosis, and baseline cognition. Lastly, we determined Braak-stage-specific conversion risk to mild cognitive impairment (MCI) or dementia. Results: Baseline global tau-PET SUVRs explained more variance (partial R2) in future cognitive decline than Centiloid across all cognitive tests (Cohen's d ~ 2, all tests p < 0.001) and diagnostic groups. Associations between tau-PET and cognitive decline remained consistent when controlling for Centiloid, while associations between amyloid-PET and cognitive decline were non-significant when controlling for tau-PET. More advanced Braak-stage was associated with gradually worsening future cognitive decline, independent of Centiloid or diagnostic group (p < 0.001), and elevated conversion risk to MCI/dementia. Conclusion: Tau-PET and Braak-staging are highly predictive markers of future cognitive decline and may be promising single-modality estimates for prognostication of patient-specific progression risk in clinical settings. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
8. Tau-PET and in vivo Braak-staging as prognostic markers of future cognitive decline in cognitively normal to demented individuals.
- Author
-
Biel, Davina, Brendel, Matthias, Rubinski, Anna, Buerger, Katharina, Janowitz, Daniel, Dichgans, Martin, and Franzmeier, Nicolai
- Subjects
- *
OLDER people , *COGNITION disorders , *MILD cognitive impairment , *DEMENTIA , *EPISODIC memory , *COGNITION , *COGNITIVE testing - Abstract
Background: To systematically examine the clinical utility of tau-PET and Braak-staging as prognostic markers of future cognitive decline in older adults with and without cognitive impairment. Methods: In this longitudinal study, we included 396 cognitively normal to dementia subjects with 18F-Florbetapir/18F-Florbetaben-amyloid-PET, 18F-Flortaucipir-tau-PET and ~ 2-year cognitive follow-up. Annual change rates in global cognition (i.e., MMSE, ADAS13) and episodic memory were calculated via linear-mixed models. We determined global amyloid-PET (Centiloid) plus global and Braak-stage-specific tau-PET SUVRs, which were stratified as positive(+)/negative(−) at pre-established cut-offs, classifying subjects as Braak0/BraakI+/BraakI–IV+/BraakI–VI+/Braakatypical+. In bootstrapped linear regression, we assessed the predictive accuracy of global tau-PET SUVRs vs. Centiloid on subsequent cognitive decline. To test for independent tau vs. amyloid effects, analyses were further controlled for the contrary PET-tracer. Using ANCOVAs, we tested whether more advanced Braak-stage predicted accelerated future cognitive decline. All models were controlled for age, sex, education, diagnosis, and baseline cognition. Lastly, we determined Braak-stage-specific conversion risk to mild cognitive impairment (MCI) or dementia. Results: Baseline global tau-PET SUVRs explained more variance (partial R2) in future cognitive decline than Centiloid across all cognitive tests (Cohen's d ~ 2, all tests p < 0.001) and diagnostic groups. Associations between tau-PET and cognitive decline remained consistent when controlling for Centiloid, while associations between amyloid-PET and cognitive decline were non-significant when controlling for tau-PET. More advanced Braak-stage was associated with gradually worsening future cognitive decline, independent of Centiloid or diagnostic group (p < 0.001), and elevated conversion risk to MCI/dementia. Conclusion: Tau-PET and Braak-staging are highly predictive markers of future cognitive decline and may be promising single-modality estimates for prognostication of patient-specific progression risk in clinical settings. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
9. Vascular Cognitive Impairment and Dementia: JACC Scientific Expert Panel.
- Author
-
Iadecola, Costantino, Duering, Marco, Hachinski, Vladimir, Joutel, Anne, Pendlebury, Sarah T., Schneider, Julie A., and Dichgans, Martin
- Subjects
- *
UNILATERAL neglect , *ALZHEIMER'S disease , *DEMENTIA , *DISABILITIES , *ETIOLOGY of diseases ,WESTERN countries - Abstract
Cognitive impairment associated with aging has emerged as one of the major public health challenges of our time. Although Alzheimer's disease is the leading cause of clinically diagnosed dementia in Western countries, cognitive impairment of vascular etiology is the second most common cause and may be the predominant one in East Asia. Furthermore, alterations of the large and small cerebral vasculature, including those affecting the microcirculation of the subcortical white matter, are key contributors to the clinical expression of cognitive dysfunction caused by other pathologies, including Alzheimer's disease. This scientific expert panel provides a critical appraisal of the epidemiology, pathobiology, neuropathology, and neuroimaging of vascular cognitive impairment and dementia, and of current diagnostic and therapeutic approaches. Unresolved issues are also examined to shed light on new basic and clinical research avenues that may lead to mitigating one of the most devastating human conditions. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
10. Understanding the role of the perivascular space in cerebral small vessel disease.
- Author
-
Brown, Rosalind, Benveniste, Helene, Black, Sandra E, Charpak, Serge, Dichgans, Martin, Joutel, Anne, Nedergaard, Maiken, Smith, Kenneth J, Zlokovic, Berislav V, and Wardlaw, Joanna M
- Subjects
- *
CEREBRAL small vessel diseases , *BRAIN blood-vessels , *CEREBRAL circulation , *BLOOD-brain barrier , *HYPOXEMIA - Abstract
Small vessel diseases (SVDs) are a group of disorders that result from pathological alteration of the small blood vessels in the brain, including the small arteries, capillaries and veins. Of the 35–36 million people that are estimated to suffer from dementia worldwide, up to 65% have an SVD component. Furthermore, SVD causes 20–25% of strokes, worsens outcome after stroke and is a leading cause of disability, cognitive impairment and poor mobility. Yet the underlying cause(s) of SVD are not fully understood. Magnetic resonance imaging has confirmed enlarged perivascular spaces (PVS) as a hallmark feature of SVD. In healthy tissue, these spaces are proposed to form part of a complex brain fluid drainage system which supports interstitial fluid exchange and may also facilitate clearance of waste products from the brain. The pathophysiological signature of PVS and what this infers about their function and interaction with cerebral microcirculation, plus subsequent downstream effects on lesion development in the brain has not been established. Here we discuss the potential of enlarged PVS to be a unique biomarker for SVD and related brain disorders with a vascular component. We propose that widening of PVS suggests presence of peri-vascular cell debris and other waste products that form part of a vicious cycle involving impaired cerebrovascular reactivity, blood-brain barrier dysfunction, perivascular inflammation and ultimately impaired clearance of waste proteins from the interstitial fluid space, leading to accumulation of toxins, hypoxia, and tissue damage. Here, we outline current knowledge, questions and hypotheses regarding understanding the brain fluid dynamics underpinning dementia and stroke through the common denominator of SVD. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
11. Cerebral small vessel disease-related protease HtrA1 processes latent TGF-β binding protein 1 and facilitates TGF-β signaling.
- Author
-
Beaufort, Nathalie, Scharrer, Eva, Kremmer, Elisabeth, Lux, Vanda, Ehrmann, Michael, Huber, Robert, Houlden, Henry, Werring, David, Haffner, Christof, and Dichgans, Martin
- Subjects
- *
CEREBRAL small vessel diseases , *TRANSFORMING growth factors , *CARRIER proteins , *LEUKOENCEPHALOPATHIES , *DEMENTIA , *BIOAVAILABILITY , *FIBRONECTINS - Abstract
High temperature requirement protein A1 (HtrA1) is a primarily secreted serine protease involved in a variety of cellular processes including transforming growth factor β (TGF-β) signaling. Loss of its activity causes cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL), an inherited form of cerebral small vessel disease leading to early-onset stroke and premature dementia. Dysregulated TGF-β signaling is considered to promote CARASIL pathogenesis, but the underlying molecular mechanisms are incompletely understood. Here we present evidence from mouse brain tissue and embryonic fibroblasts as well as patient skin fibroblasts for a facilitating role of HtrA1 in TGF-β pathway activation. We identify latent TGF-β binding protein 1 (LTBP-1), an extracellular matrix protein and key regulator of TGF-β bioavailability, as a novel HtrA1 target. Cleavage occurs at physiological protease concentrations, is prevented under HtrA1-deficient conditions as well as by CARASIL mutations and disrupts both LTBP-1 binding to fibronectin and its incorporation into the extracellular matrix. Hence, our data suggest an attenuation of TGF-β signaling caused by a lack of HtrA1-mediated LTBP-1 processing as mechanism underlying CARASIL pathogenesis. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
12. The Determinants of Dementia After Stroke ( DEDEMAS) Study: protocol and pilot data.
- Author
-
Wollenweber, Frank A., Zietemann, Vera, Rominger, Axel, Opherk, Christian, Bayer-Karpinska, Anna, Gschwendtner, Andreas, Coloma Andrews, Lisa, Bürger, Katharina, Duering, Marco, and Dichgans, Martin
- Subjects
- *
DEMENTIA , *CEREBROVASCULAR disease patients , *MAGNETIC resonance imaging , *RETINAL imaging , *POSITRON emission tomography ,HEALTH of patients - Abstract
Rationale About 20% of stroke patients develop dementia within a few months after their event, but the determinants and mechanisms of poststroke dementia are insufficiently understood. Aims To identify and characterize the determinants of cognitive impairment poststroke. Design Observational prospective study in patients with acute stroke and no prior dementia. Six hundred subjects will be characterized by detailed interview, standardized clinical examinations, biometric measures (intima-media thickness, waist-hip ratio, and ankle-brachial index), multimodal imaging (magnetic resonance imaging, fluorodeoxyglucose-positron emission tomography ( FDG-PET), amyloid-positron emission tomography (amyloid- PET), and retinal imaging), analysis of biomarkers derived from blood and cerebrospinal fluid, and detailed cognitive testing at repeat time points. Patients will be followed for five-years with a total of five personal visits and three telephone interviews. Study Outcomes Primary end-point is the occurrence of poststroke dementia. Secondary end-points include poststroke cognitive impairment-no dementia, stroke recurrence, and death. Predictive factors for poststroke dementia will be identified by multiple Cox proportional-hazards model. Results Baseline characteristics of the first 71 patients (study inclusion between May 2011 and August 2012) are as follows: median age, 70 years (interquartile range, 65-75); female gender, 25 (35%); median National Institutes of Health Stroke Scale at admission, 2 (1-4); and etiological stroke subtypes according to TOAST classification, 15% large artery disease, 18% small vessel disease, 35% cardioembolic, and 32% undetermined or multiple competing etiologies. Discussion This study will provide insights into the mechanisms of poststroke dementia and hold the potential to identify novel diagnostic markers and targets for preventive therapies. The study is registered at ( NCT01334749) and will be extended as a multicenter study starting 2013. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
13. White-Matter Lesions without Lacunar Infarcts in CADASIL.
- Author
-
Benisty, Sarah, Reyes, Sonia, Godin, Ophelia, Hervé, Dominique, Zieren, Nikola, Jouvent, Eric, Zhu, Yicheng, During, Marco, Dichgans, Martin, and Chabriat, Hugues
- Subjects
- *
COGNITION , *DEMENTIA , *PATIENTS , *MILD cognitive impairment , *NEURODEGENERATION - Abstract
To better characterize the clinical spectrum related to white-matter hyperintensities (WMH) in small vessel disease, 66 patients with WMH but without any lacunar infarct were selected out of a cohort of 248 CADASIL individuals. Characteristics of these patients were compared to those of patients with lacunar infarcts. Relationships between the normalized volume of WMH (nWMH), presence of microhemorrhages, brain parenchymal fraction (BPF). and cognitive performances were assessed. The Trail Making Test (TMT) A and B times, Mattis Dementia Rating Scale (MDRS) total score, attention subscore, verbal fluency score and delayed memory recall were significantly correlated with nWMH but not with BPF. Presence of microhemorrhages was associated with worse TMT B time and attention MDRS subscore after adjustment for WMH. All subjects had Mini-Mental Status Examination scores ≥24 and presented with no or only mild disability. These results suggest that CADASIL patients with isolated WMH can present with executive and attention deficit but not with severe disability and that additional lesions are needed to cause significant disability and/or dementia. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
14. Hippocampal volume is an independent predictor of cognitive performance in CADASIL
- Author
-
O'Sullivan, Mike, Ngo, Elmar, Viswanathan, Anand, Jouvent, Eric, Gschwendtner, Andreas, Saemann, Philipp G., Duering, Marco, Pachai, Chahin, Bousser, Marie-Germaine, Chabriat, Hugues, and Dichgans, Martin
- Subjects
- *
HUNTINGTON disease , *DEMENTIA , *PSYCHOSES , *ISCHEMIA - Abstract
Abstract: Recent evidence suggests that hippocampal changes are present in vascular cognitive impairment but their importance and relationship with ischaemic mechanisms remain controversial. To investigate these issues we performed MRI and cognitive assessment in a large cohort (n =144) of patients with CADASIL, a hereditary small vessel disease and model of pure vascular cognitive impairment. Dementia status was ascribed according to DSM-IV and global cognitive function assessed with the Minimental State Examination (MMSE) and Mattis Dementia Rating Scale (MDRS). Hippocampal volume (HV) correlated with age (r =−0.33, p <0.001), brain volume (r =0.39, p <0.001) and lacunar lesion volume (r =−0.23, p =0.008), but not white matter lesions or microhaemorrhages. HV was reduced in dementia (2272±333mm3 versus 2642±349mm3, p <0.001) in the whole cohort and the subgroup progressing to dementia before age 60. HV correlated with MMSE (r =0.30, p <0.001), MDRS (r =0.40, p <0.001) and in a multivariate model predicted cognition independent of typical vascular lesions and whole brain atrophy. These findings strengthen the view that hippocampal atrophy is an important pathway of cognitive impairment in vascular as well as degenerative disease. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
15. Influence of SORL1 gene variants: Association with CSF amyloid-β products in probable Alzheimer's disease
- Author
-
Kölsch, Heike, Jessen, Frank, Wiltfang, Jens, Lewczuk, Piotr, Dichgans, Martin, Kornhuber, Johannes, Frölich, Lutz, Heuser, Isabella, Peters, Oliver, Schulz, Jörg B., Schwab, Sibylle G., and Maier, Wolfgang
- Subjects
- *
ALZHEIMER'S disease , *DEMENTIA , *PATHOLOGY , *DISEASES in older people - Abstract
Abstract: SORL1 gene variants were described as risk factors of Alzheimer''s disease (AD). We investigated the association of four SORL1 variants with CSF levels of Aβ42 and Aβ40 in 153 AD patients recruited from a multicenter study of the German Competence Net Dementias. Only one SORL1 SNP was associated with altered Aβ42 levels in the single marker analysis (SNP21: p =0.011), the other SNPs did not show an association with Aβ42 or Aβ40 CSF levels. Haplotype analysis identified a three marker SORL1 haplotype consisting of SNP19 T-allele, SNP21 G-allele and SNP23 A-allele (T/G/A) which was associated with reduced Aβ42 CSF levels in AD patients (p =0.003). Aβ40 levels were also lower in carriers of this haplotype; however, this did not reach statistical significance (p =0.15). We found a SORL1 haplotype which was associated with CSF levels of amyloid-β cleavage products, measured as altered levels of Aβ42. Thus our data suggest that SORL1 gene variants might influence AD pathology. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
16. The pattern of cognitive performance in CADASIL: a monogenic condition leading to subcortical ischemic vascular dementia.
- Author
-
Peters, Nils, Opherk, Christian, Danek, Adrian, Ballard, Clive, Herzog, Jürgen, Dichgans, Martin, and Herzog, Jürgen
- Subjects
- *
DEMENTIA , *PSYCHOSES , *ISCHEMIA , *CLINICAL medicine , *COGNITION disorders , *VASCULAR diseases - Abstract
Objective: Subcortical ischemic vascular lesions, which are closely related to small vessel disease, are a common substrate of cognitive impairment and dementia. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is a monogenic variant of small vessel disease resulting from mutations in NOTCH3. Mutation carriers almost invariably develop cognitive deficits and eventually dementia. The current study describes the profile of cognitive abnormalities in CADASIL subjects.Method: A cross-sectional study of 65 mutation carriers (mean age=47.3 years, SD=10.5) and 30 matched comparison subjects (mean age=47.2 years, SD=14.0) was conducted. Participants underwent a series of assessments that included ratings of global cognition, the cognitive portion of the Vascular Dementia Assessment Scale, and specific tests of executive function and attention with measures of processing speed and error monitoring.Results: CADASIL subjects had pronounced impairments of the timed measures (Stroop II and III, Trail Making Test, symbol digit, digit cancellation). Measures of error monitoring (Stroop III, Trail Making Test, symbol digit, maze task) were also significantly affected but to a lesser extent. Prominent deficits further included verbal fluency and ideational praxis. Recall, orientation, and receptive language skills were largely preserved. Subgroup analyses indicated a similar profile in subjects with early and advanced impairment of global cognitive performance.Conclusions: The findings highlight processing speed as the most substantial area of cognitive impairment in CADASIL subjects, with less pronounced yet significant deficits in other aspects of executive performance and attention. This profile of cognitive impairment is present at an early stage and enables the construction of targeted test batteries for clinical trials. It is hypothesized that the profile of dysfunction described here represents the core of the cognitive syndrome associated with small vessel disease and subcortical ischemic vascular lesions. [ABSTRACT FROM AUTHOR]- Published
- 2005
- Full Text
- View/download PDF
17. Dementia after stroke due to intracerebral haemorrhage.
- Author
-
Salman, Rustam Al-Shahi, McGoohan, Katie, Rodrigues, Mark, Dichgans, Martin, and Al-Shahi Salman, Rustam
- Subjects
- *
TREATMENT of dementia , *CEREBRAL amyloid angiopathy , *NEURODEGENERATION , *CEREBRAL hemorrhage , *DISEASE complications , *FEMALES , *DISEASES , *DEMENTIA , *STROKE - Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.